{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009681","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.173787+00:00","generated_at":"2026-05-21T23:46:11.191855+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oncocyte Q1 revenue $2.14M, gross margin 62%; transplant trial gets IRB approval","bullets":["Q1 2025 pharma services revenue $2.14M with 62% gross margin, up from 40% in Q4 2024.","Net loss $6.7M ($0.26 per share); non-GAAP loss from operations $5.0M.","Clinical trial design completed, central IRB approved; three top-10 US transplant centers expected to participate.","Ten leading transplant centers now using GraftAssure RUO kits; company plans to rename in Q2.","Cash balance $32.7M at quarter-end, including $28.7M net from February offering; Q1 operating cash use $5.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009681","json":"https://secwatch.observer/filing/0001641172-25-009681.json","markdown":"https://secwatch.observer/filing/0001641172-25-009681.md","text":"https://secwatch.observer/filing/0001641172-25-009681.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225009681/0001641172-25-009681-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225009681/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:46:11.191855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}